Table 1. Complete medication history, ACTH, Insulin, and Glucose values for each case.
| Case # | Date | Medication (other than dopaminergic) | ACTH (pmol/) | Insulin (pmol/l) | Glucose (mmol/l) |
|---|---|---|---|---|---|
| Case 1 | |||||
| Aug-2019 | • | 4.8 | 647 | 6.1 | |
| Oct-2019 | 150 mg/day canagliflozin | • | 465 | 5.5 | |
| Jan-2020 | 300 mg/day canagliflozin | 4.5 | 119 | 4.5 | |
| Case 2 | |||||
| Feb-2020 | • | 4.1 | >1,200* | 6.2 | |
| Mar-2020 | 22 mg/kg metformin BID | 2.5 | 334 | 5.2 | |
| Apr-2020 | 33 mg/kg metformin BID 48 mg/day levothyroxine 28 g/day InsulinWisea |
4.5 | 542 | 5.6 | |
| May-2020 | 45 mg/kg metformin BID 48 mg/day levothyroxine |
2.8 | >1,200* | 6.1 | |
| Jul-2020 | 300 mg/day canagliflozin | 2.9 | 163 | 4.2 | |
| Case 4 | |||||
| Jan-2018 | • | TRH Stimulation Pre: 6.6 Post: 30.6 |
929 | 6.0 | |
| Oct-2019 | • | • | >1,200* | • | |
| Nov-2019 | 30 mg/kg metformin BID | • | 897 | • | |
| Mar-2020 | 300 mg/day canagliflozin | 3.4 | 192 | 4.9 | |
| Case 5 | |||||
| Oct-2019 | 24 mg/day levothyroxine | • | >1,200* | 9.0 | |
| Apr-2020 | 24 mg/day levothyroxine 30 mg/kg metformin BID |
5.4 | >1,200* | 7.4 | |
| May-2020 | 24 mg/day levothyroxine 30 mg/kg metformin TID |
5.6 | >1,200* | 7.0 | |
| Aug-2020 | 24 mg/day levothyroxine 30 mg/kg metformin TID |
7.8 | 988 | • | |
| Sep-2020 | 24 mg/day levothyroxine 150 mg/day canagliflozin |
9.9 | 610 | 6.0 | |
| Nov-2020 | 24 mg/day levothyroxine 150 mg/day canagliflozin |
• | 396 | • | |
| Case 6 | |||||
| Oct-18 | • | 7.9 | 614 | 5.1 | |
| Jan-19 | • | TRH Stimulation Pre: 3.9 Post: 29.5 |
• | • | |
| Nov-2020 | 300 mg/day canagliflozin | • | • | • | |
| Jan-2020 | 150 mg/day canagliflozin | • | • | • | |
| Mar-2020 | 150 mg/day canagliflozin | 2.4 | 122 | • | |
| Case 7 | |||||
| Oct-1920 | • | 4.6 | • | • | |
| Apr-2020 | 30 mg/kg BID metformin | • | 551 | • | |
| May-2020 | 30 mg/kg BID metformin | • | 436 | 6.0 | |
| Jul-2020 | 300 mg/day canagliflozin | • | 206 | • | |
| Sep-2020 | 300 mg/day canagliflozin | • | 58 | 5.1 | |
| Case 8 | |||||
| Nov-2019 | • | 6.3 | >1,200* | 6.1 | |
| Feb-2020 | 300 mg/day canagliflozin | 4.1 | 146 | 5.0 | |
| Apr-2020 | 150 mg/day canagliflozin | 3.8 | 253 | 5.4 | |
| Jul-2020 | 150 mg/day canagliflozin | 8.6 | 117 | 5.1 | |
| Aug-2020 | 150 mg/day canagliflozin | 7.1 | 156 | 4.9 | |
| Sept-2020 | 150 mg/day canagliflozin | 5.4 | 335 | 5.4 | |
| Case 9 | |||||
| Apr-2020 | • | 4.9 | 532 | 8.9 | |
| Jul-2020 | • | 5.1 | 555 | 10.4 | |
| Sep-2020 | 150 mg/day canagliflozin | 4.6 | 344 | 5.8 | |
| Case 10 | |||||
| June 2014 | 45 mg/day levothyroxine | • | • | • | |
| Nov-2018 | 45 mg/day levothyroxine 28 g/day InsulinWisea |
2.95 | 531 | 5.5 | |
| Jul-2020 | 20 mg/kg BID metformin | 4.45 | 1,190 | 6.3 | |
| Jan-2021 | 300 mg/day canagliflozin | • | 245 | • |
*: Upper limit of assay; (a) InsulinWiseTM (KPP, Kentucky, USA) per 28 g dose: 2,100 mg leucine; 750 mg resveratrol; 500 mg quercetin; 470 mg proline; 395 mg alanine; (•): No medication other than dopamine agonist, no laboratory tests.